Highlights Amplia Therapeutics Limited

Equities

ATX

AU0000023822

Delayed Australian S.E. Other stock markets 10:52:17 21/06/2024 am IST			5-day change	1st Jan Change
0.066 ^AUD	+8.20%		-1.49%	-17.50%

30/05	Amplia Therapeutics Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI
15/05	Amplia Therapeutics Completes AU$4.27 Million Entitlement Offer; Shares Up 9%	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Amplia Therapeutics Limited Reports Earnings Results for the Full Year Ended March 31, 2024	30/05	CI
Amplia Therapeutics Completes AU$4.27 Million Entitlement Offer; Shares Up 9%	15/05	MT
Amplia Therapeutics to Raise AU$4.3 Million for Cancer Trials, Drug Capsule Manufacturing	16/04	MT
Amplia Therapeutics Secures US FDA Clearance for Proposed Pancreatic Cancer Trial	18/01	MT
Amplia Therapeutics Limited Announces FDA Clearance of it's IND for Pancreatic Cancer Trial in US	18/01	CI
Amplia Therapeutics Secures South Korean Regulatory Approval for Pancreatic Cancer Trial; Shares Up 3%	04/12	MT
Amplia Therapeutics Limited Reports Earnings Results for the Half Year Ended September 30, 2023	21/11	CI
Amplia Therapeutics Receives AU$2.4 Million R&D Tax Rebate	19/23/19	MT
Amplia Therapeutics Limited Reports Earnings Results for the Full Year Ended March 31, 2023	30/23/30	CI
Amplia Therapeutics to Enter Research Collaboration with CSIRO; Shares Rise 7%	22/23/22	MT
Amplia Therapeutics Secures Clearance for Third Dose Cohort of Pancreatic Cancer Trial	11/23/11	MT
Amplia Therapeutics Limited Announces Completion of Enrolment of the Second Cohort of Patients in the Ongoing Phase 1b/2a ACCENT Clinical Trial in Frontline Patients with Pancreatic Cancer	28/23/28	CI
Amplia Therapeutics Limited Announces First Patient Recruited to Cohort 2 of Accent Trial in Pancreatic Cancer	01/23/01	CI
Amplia Therapeutics Limited Announces Dose Escalation Approved in ACCENT Clinical Trial of AMP945	11/23/11	CI
Amplia Therapeutics Limited Reports Earnings Results for the Half Year Ended September 30, 2022	18/22/18	CI
Amplia Therapeutics Limited Reports New Data of its Second Focal Adhesion Kinase Inhibitor AMP886 for the Treatment of Acute Myeloid Leukemia	03/22/03	CI
Amplia Therapeutics Limited Announces First Patient Recruited to ACCENT Trial in Pancreatic Cancer	02/22/02	CI
Amplia Therapeutics Changes Principal Place of Business	24/22/24	MT
Amplia Therapeutics Limited Shows AMP945 Efficacy in Model of Lung Fibrosis	02/22/02	CI
Amplia Therapeutics Limited Reports Earnings Results for the Full Year Ended March 31, 2022	30/22/30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Amplia Therapeutics Limited

Equities

ATX

AU0000023822

Highlights

Filters